

Your Drug Efficacy.

Now Revealed.

Make the Decisions that matter. Now.

- Today's preclinical brain drug discovery lacks predictive biomarkers of inhuman efficacy, leading to dramatic attrition rates at Clinical Phases II & III.
- Inspired by the clinical practice, we apply quantitative EEG methods (qEEG) on translational models to address this unmet need for predictivity.
- Neural network oscillations are indeed known to be altered in various brain disorders. Disease-specific oscillatory signatures can be used as surrogate biomarkers for drug discovery.
- Named Cue®, our powerful qEEG-based technology platform was designed to help our clients make better-informed decisions as it delivers reliable insights on drug efficacy right from brain oscillations.

Powerful Pharmacodynamic assays.

- Cue® combines high-end brain recording capabilities, proprietary signal processing, clinically-relevant animal models mimicking human diseases, and a team with strong skillsets in Neuroscience and Pharmacology.
- To your specific question, Cue® delivers precise functional profiling of your compounds with high reproducibility levels, objective endpoints and robust datasets.

Compound testing capabilities that include:

- Surface to deep brain recording
- In vivo exclusive assays
- Freely-moving translational models
- Crossover clinical protocols
- Ability to compare to reference drugs

Unbiased outcomes. Delivered.



Neuroscience expertise.

F EPILEPSY

- Partial and generalized epilepsies
- Stable and spontaneous discharges
- Biomarkers: SWD and HPD
- Models: MTLE mouse and GAERS rat
- Non-convulsive models
- Anti-epileptic effect- Derisking
- Disease-modifying Epileptogenesis Screening

***** MOVEMENT

- Parkinson's, Dyskinesia and Essential Tremor
- Motor-related abnormal oscillations
- Biomarkers: BetaPARK and GammaPARK
- Models: 6-OHDA rat and Harmaline mouse
- Antidyskinetic effect anti-parkinsonian effect
- Acute or chronic protocols

⇔ COGNITIVE

- Schizophrenia, Alzheimer's disease, Autism
- Pharmaco-induced oscillations
- Auditory-evoked potentials
- Biomarkers: ASSR and AERPs
- Defects in information processing
- Pro-cognitive effect

EXPLORATORY

- Want to check your compound effect on brain oscillations?
- Wishing to phenotype your own model?
- Having massive EEG data to analyze?

You can then benefit from our **Exploratory program** to answer these questions. We also offer you to move forward by taking advantage of our **Derisking program** to unveil potential side effects (pro-epileptic, pro-kinetic, toxicity...) of your compound.

Partnering with SynapCell



We're experts in Neuroscience, Pharmacology, and Brain Surgery.



Over 13 years supporting preclinical drug development for international companies of all sizes.



Quality management system, with SOPs. Animal welfare and EU guidelines compliance.



Strong Research & Innovation. Solid Pipeline. No outsourcing.

- > Personalized Study design
- > 3 to 6 weeks to result
- > Comprehensive Report



SYNERGY Building ZAC Isiparc 38330 Saint-Ismier France

hello@synapcell.com www.synapcell.com

PREDICTIVE BIOMARKERS DECISION-MAKING ASSAYS CNS EXPERTISE

SynapCell is a preclinical stage biotechnology company focused on Central Nervous System disorders, Since 2005, our CRO activity supports international pharmaceutical companies in revealing the therapeutic potential of their compounds in development. Cue®, our predictive decision-making solution comes with a large set of assays specifically designed for Drug Discovery applications. Quantitative, Cue® uses the power and sensitivity of Electro-Encephalography (EEG) to identify functional biomarkers of neurological diseases in vivo, with remarkable human translatability. Our returning customers in USA, Japan, Korea or Europe helped the company establish a solid reputation on the market and is the basis for long-lasting successful business partnerships.